These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8622049)

  • 1. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.
    Saven A; Cheung WK; Smith I; Moyer M; Johannsen T; Rose E; Gollard R; Kosty M; Miller WE; Piro LD
    J Clin Oncol; 1996 Mar; 14(3):978-83. PubMed ID: 8622049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration.
    Liliemark J; Albertioni F; Hassan M; Juliusson G
    J Clin Oncol; 1992 Oct; 10(10):1514-8. PubMed ID: 1357107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion.
    Sonderegger T; Betticher DC; Cerny T; Lauterburg BH
    Cancer Chemother Pharmacol; 2000; 46(1):40-2. PubMed ID: 10912576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of population pharmacokinetics to cladribine.
    Lindemalm S; Savic RM; Karlsson MO; Juliusson G; Liliemark J; Albertioni F
    BMC Pharmacol; 2005 Mar; 5():4. PubMed ID: 15757511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration.
    Liliemark J; Albertioni F; Juliusson G; Eksborg S
    Cancer Chemother Pharmacol; 1996; 38(6):536-40. PubMed ID: 8823495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
    Weiss GR; Kuhn JG; Rizzo J; Smith LS; Rodriguez GI; Eckardt JR; Burris HA; Fields S; VanDenBerg K; von Hoff DD
    Cancer Chemother Pharmacol; 1995; 35(5):397-402. PubMed ID: 7850921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
    Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y
    Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
    Rodriguez GI; Kuhn JG; Weiss GR; Hilsenbeck SG; Eckardt JR; Thurman A; Rinaldi DA; Hodges S; Von Hoff DD; Rowinsky EK
    Blood; 1998 Mar; 91(5):1533-41. PubMed ID: 9473217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia.
    Albertioni F; Lindemalm S; Reichelova V; Pettersson B; Eriksson S; Juliusson G; Liliemark J
    Clin Cancer Res; 1998 Mar; 4(3):653-8. PubMed ID: 9533533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
    Robak T; Korycka A; Robak E
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):23-38. PubMed ID: 18221024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
    Saven A; Kawasaki H; Carrera CJ; Waltz T; Copeland B; Zyroff J; Kosty M; Carson DA; Beutler E; Piro LD
    J Clin Oncol; 1993 Apr; 11(4):671-8. PubMed ID: 8097527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.
    Savic RM; Novakovic AM; Ekblom M; Munafo A; Karlsson MO
    Clin Pharmacokinet; 2017 Oct; 56(10):1245-1253. PubMed ID: 28255849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
    von Rohr A; Schmitz SF; Tichelli A; Hess U; Piguet D; Wernli M; Frickhofen N; Konwalinka G; Zulian G; Ghielmini M; Rufener B; Racine C; Fey MF; Cerny T; Betticher D; Tobler A;
    Ann Oncol; 2002 Oct; 13(10):1641-9. PubMed ID: 12377655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.
    Juliusson G; Heldal D; Hippe E; Hedenus M; Malm C; Wallman K; Stolt CM; Evensen SA; Albertioni F; Tjønnfjord G
    J Clin Oncol; 1995 Apr; 13(4):989-95. PubMed ID: 7707128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
    Rummel MJ; Chow KU; Jäger E; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
    Ann Oncol; 1999 Jan; 10(1):115-7. PubMed ID: 10076731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.